Clinical Research

Global Biotech Weekly

As the American Society of Clinical Oncology Conference (ASCO25) approaches, we’re spotlighting key data and late-breaking presentations to watch. With abstracts scheduled for release on 23 May and the conference taking place on 30 May 2025, this preview offers investors ample time to conduct furthe

Global Biotech Weekly

This week we focus on the catalysts due for Phase 1 and 2 trials. At this stage in development, these trials aim to test the safety, side effects, and best dose of a new treatment. Data from these trials can also review initial efficacy data that will then be used to compare with the drug’s efficacy

Global Biotech Weekly

This week, we are revisiting the small to mid-cap PDUFA left for the quarter. At this stage in development, these trials aim to test the safety, side effects, and best dose of a new treatment. UroGen Pharma (NASDAQ: URGN) has a market cap of US$181m and a float of approximately 43.76m shares. The co A regulatory decision is expected on 13 June 2025, for UGN-102 (VesiGel), a mitomycin-based intravesical th Nuvation Bio (NYSE: NUVB) is a clinical-stage oncology company with a market cap of approximately US$784m a A PDUFA date of 23 June 2025, has been set for Taletrectinib, a selective ROS1/NTRK inhibitor under priorit Unicycive Therapeutics (NASDAQ: UNCY) is a micro-cap company with a valuation near US$65m. It has limited r The FDA has assigned a PDUFA date of 28 June 2025, for Oxylanthanum Carbonate (OLC), a novel lanthanum-base

Biotech Stock Updates

We focus to look at key drivers of biotech stocks' price movement on 23 May 2025. Gyre Therapeutics (NASDAQ: GYRE) priced its public offering of 2.22m shares at US$9.00 each, expecting approximately US$20m in gross proceeds. Underwriters have a 30-day option to buy another 333k shares. Shares closed IMUNON (NASDAQ: IMNN) shares closed up 179% at US$1.16 after it reported that its Phase 2 OVATION 2 study showed significant survival improvements for advanced ovarian cancer patients treated with IMNN-001 plus standar Merus N.V. (NASDAQ: MRUS) reported interim phase 2 data for petosemtamab plus pembrolizumab in head and neck cancer showed a 63% response rate, 79% 12-month OS, and 9-month median PFS in 43 patients, leading Needham to Prothena Corporation (NASDAQ: PRTA) announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based on these resu Immix Biopharma (NASDAQ: IMMX) shares closed down 17% at US$1.99 following NXC-201 data which demonstrated a 71% complete response rate (5/7 patients) in relapsed/refractory AL Amyloidosis in the NEXICART-2 trial and w BriaCell Therapeutics (NASDAQ: BCTX) reported at ASCO 2025 that patients receiving its selected Phase 3 Bria-IMT formulation showed significantly improved PFS (3.6 vs. 2.6 months) and OS (13.4 vs. 6.9 months) compared Biodexa Pharmaceuticals (NASDAQ: BDRX) will hold a 11 June 2025 meeting to propose a share capital reorganization and seek approval to issue new shares for acquisitions and financings, with the latest analyst rating ma

V小姐

2 months ago